时间标签：数据日期 2026-11-03 · 生成时间 2026-11-03 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/31 – 2026/11/03 ｜ 情报发生日期 2026-11-03
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
摘要（PubMed 原文节选）
Alzheimer's disease (AD) remains one of the most difficult neurodegenerative disorders to treat. Therapeutic failure is driven mainly by two barriers: the multifactorial pathological network of AD and the limited access of most therapeutics to the brain imposed by the blood-brain barrier (BBB). Conventional symptomatic drugs and emerging antibody-based therapies provide clinical benefit, but they do not fully address the interacting processes involving amyloid-β (Aβ) accumulation, Tau pathology, neuroinflammation, mitochondrial dysfunction, oxidative stress, and synaptic impairment. In this review, we discuss nanomedicine as an integrated platform for AD intervention. We summarize the major …
对本项目的价值
参考价值：属「线粒体质量控制与氧化应激」方向；脑老化 / 神经退行 / 认知栏目可用作本项目文献库与综述素材。 ｜ 价值分 1.5/5（★★☆☆☆）
全文不可及原因
标注 OA 但 PDF 下载失败或未通过题名指纹归属校验
原文题录
- 中文题名：阿尔茨海默病纳米医学：病理网络调控、血脑屏障递送与临床转化框架
- 英文标题：Nanomedicine for Alzheimer's Disease: A Stage-Matched Framework Integrating Pathological Network Modulation, Blood-Brain Barrier Delivery, and Clinical Translation.
- 期刊与标识：Pharmacol Res · PMID 42966482 · DOI 10.1016/j.phrs.2026.109709 · EDAT 2026-10-31